MSD launches first Herceptin biosimilar in UK
Seminarul științific BIOSIM – DDS Diagnostic
Medicamente biosimilare, de ce are nevoie România să le adopte la scară largă | DCMedical.ro
Integrated Biopharma AND Pharma Solution on LinkedIn: Eculizumab biosimilar gets positive CHMP opinion
Samsung Biologics inks biosimilar manufacturing deal with Pfizer
Biosimilar uptake will take more than competitive pricing
US FDA accepts Biocon's cancer drug application for review - The Economic Times
Tocilizumab biosimilar successfully meets primary, secondary endpoints in Phase I study: Dr Reddy's Labs
Expert: generation of biobetters could push out biosimilar development
Biosimilar Drug Master Class | McKesson
Russia approves first ever biosimilar of Serono's MS drug Rebif
Switchback BioSim Innovations is excited to transition into our new space with expanded lab space, new project development labs, and a larger team! We... | By Switchback Medical | Facebook
Switchback BioSim Innovations is excited to transition into our new space with expanded lab space, new project development labs, and a larger team! We... | By Switchback Medical | Facebook
Biocon, Mylan Launch Fulphila, Biosimilar Pegfilgrastim in Australia
Seminarul științific BIOSIM – DDS Diagnostic
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition | Fierce Pharma
Mylan and Biocon Herceptin biosimilar delayed by FDA for 3 months | Fierce Pharma
BioScript Solutions | What is a biosimilar?
ADVANZ PHARMA enters into an exclusive agreement with Alvotech to commercialise a proposed biosimilar to Xolair® (omalizumab) | ADVANZ PHARMA
Biosimilar Products - BioProcess InternationalBioProcess International
Biosim - recenzii, fotografii, număr de telefon și adresă - Centre medicale din Târgu Mureș - Nicelocal.ro
Interchangeability of biosimilars in the EU – the industry impact
Zilele Spitalului Universitar de Urgenta Militar Central Dr. Carol Davila – Galerie multimedia
Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort - Gros - 2023 - United European Gastroenterology Journal - Wiley Online Library
BioSim Research Group | Porto
Foundation hosts event to launch report on generic & biosimilar medicine manufacturers | Access to Medicine Foundation
Sandoz Biosimilar Technical Development Centre, Slovenia
